<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33976533</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1177-8881</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Drug design, development and therapy</Title>
          <ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data.</ArticleTitle>
        <Pagination>
          <StartPage>1811</StartPage>
          <EndPage>1817</EndPage>
          <MedlinePgn>1811-1817</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S240865</ELocationID>
        <Abstract>
          <AbstractText>Zonisamide is an anti-epileptic medication with multiple mechanisms of action and a favorable safety profile. Zonisamide may interact with Lewy body dementia pathophysiology through a mechanism unrelated to its original indication. Zonisamide has shown efficacy as adjunct therapy for the management of motor symptoms in patients with Parkinson's disease (PD). Given that dementia with Lewy bodies (DLB) and PD are considered subtypes of a Lewy body disease spectrum, zonisamide was investigated for the treatment of parkinsonism in DLB. Phase II and phase III clinical trials were conducted in patients with DLB in Japan. In both studies, participants were randomized to receive 12 weeks of zonisamide 25 or 50 mg/day or placebo. Zonisamide significantly improved the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) without affecting the Mini-Mental State Examination (MMSE) or Neuropsychiatry Inventory-10 (NPI-10) scores at week 12. In 2018, zonisamide received Japanese regulatory approval for the additional indication of parkinsonism in DLB. This review discusses the emerging clinical data on zonisamide in the field of DLB.</AbstractText>
          <CopyrightInformation>© 2021 Tousi and Leverenz.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tousi</LastName>
            <ForeName>Babak</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leverenz</LastName>
            <ForeName>James B</ForeName>
            <Initials>JB</Initials>
            <AffiliationInfo>
              <Affiliation>Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Des Devel Ther</MedlineTA>
        <NlmUniqueID>101475745</NlmUniqueID>
        <ISSNLinking>1177-8881</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">clinical trial</Keyword>
        <Keyword MajorTopicYN="N">dementia with Lewy bodies</Keyword>
        <Keyword MajorTopicYN="N">parkinsonism</Keyword>
        <Keyword MajorTopicYN="N">zonisamide</Keyword>
      </KeywordList>
      <CoiStatement>Dr Babak Tousi reports being a consultant for Eisai and Biogen, and grants from the Alzheimer’s Drug Discovery Foundation, outside the submitted work. Dr James JB Leverenz reports grants from the NIH, during the conduct of the study; personal fees from Acadia, personal fees from Biogen, personal fees from Eisai, personal fees from Takeda, and grants from GE Healthcare, outside the submitted work. The authors report no other conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>7</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33976533</ArticleId>
        <ArticleId IdType="pmc">PMC8106402</ArticleId>
        <ArticleId IdType="doi">10.2147/DDDT.S240865</ArticleId>
        <ArticleId IdType="pii">240865</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. doi:10.1212/WNL.0000000000004058</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004058</ArticleId>
            <ArticleId IdType="pmc">PMC5496518</ArticleId>
            <ArticleId IdType="pubmed">28592453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tousi B. Diagnosis and management of cognitive and behavioral changes in dementia with Lewy bodies. Curr Treat Options Neurol. 2017;19(11). doi:10.1007/s11940-017-0478-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11940-017-0478-x</ArticleId>
            <ArticleId IdType="pubmed">28990131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248–2250. doi:10.1002/mds.22322</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.22322</ArticleId>
            <ArticleId IdType="pubmed">18823039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata M, Odawara T, Hasegawa K, et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: a Phase 3 randomized clinical trial. Parkinsonism Relat Disord. 2020;76:91–97. doi:10.1016/j.parkreldis.2019.12.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.parkreldis.2019.12.005</ArticleId>
            <ArticleId IdType="pubmed">31982288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S. Food and Drug Administration. Zonisamide approvable labeling [Internet]. Approved labeling text; 2000. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20789lbl.pdf. Accessed April20, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15(1):67–73. doi:10.1016/0920-1211(93)90011-U</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0920-1211(93)90011-U</ArticleId>
            <ArticleId IdType="pubmed">8325280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seino M. Review of zonisamide development in Japan. Seizure. 2004;13:S2–S4. doi:10.1016/j.seizure.2004.04.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.seizure.2004.04.015</ArticleId>
            <ArticleId IdType="pubmed">15511683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verrotti A, Loiacono G, Di Sabatino F, Zaccara G. The adverse event profile of zonisamide: a meta-analysis. Acta Neurol Scand. 2013. doi:10.1111/ane.12147</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ane.12147</ArticleId>
            <ArticleId IdType="pubmed">23763367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves motor function in Parkinson disease: a Randomized, Double-Blind Study. Neurology. 2007;68(1):45–50. doi:10.1212/01.wnl.0000250236.75053.16</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000250236.75053.16</ArticleId>
            <ArticleId IdType="pubmed">17200492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006;26(10):1199–1202. doi:10.1111/j.1468-2982.2006.01191.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-2982.2006.01191.x</ArticleId>
            <ArticleId IdType="pubmed">16961786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammadianinejad SE, Abbasi V, Sajedi SA, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol. 2011;34(4):174–177. doi:10.1097/WNF.0b013e318225140c</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNF.0b013e318225140c</ArticleId>
            <ArticleId IdType="pubmed">21738025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinrys G, Vasconcelos E Sa D, Nery F. Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract. 2007;61(6):1050–1053. doi:10.1111/j.1742-1241.2007.01365.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-1241.2007.01365.x</ArticleId>
            <ArticleId IdType="pubmed">17504366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (Zonegran) in the treatment of essential tremor. Mov Disord. 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17149715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gluck MR, Santana LA, Granson H, Yahr MD. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity. J Neural Transm. 2004;111(6):713–724. doi:10.1007/s00702-004-0107-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-004-0107-1</ArticleId>
            <ArticleId IdType="pubmed">15168218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miwa H, Hama K, Kajimoto Y, Kondo T. Effects of zonisamide on experimental tremors in rats. Parkinsonism Relat Disord. 2008;14(1):33–36. doi:10.1016/j.parkreldis.2007.05.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.parkreldis.2007.05.008</ArticleId>
            <ArticleId IdType="pubmed">17587636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishijima H, Miki Y, Ueno S, Tomiyama M. Zonisamide enhances motor effects of levodopa, not of apomorphine, in a rat model of Parkinson’s disease. Parkinsons Dis. 2018;2018:1–7. doi:10.1155/2018/8626783</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/8626783</ArticleId>
            <ArticleId IdType="pmc">PMC6312621</ArticleId>
            <ArticleId IdType="pubmed">30662707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22(3):193–205. doi:10.1016/0920-1211(95)00078-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0920-1211(95)00078-X</ArticleId>
            <ArticleId IdType="pubmed">8991786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonsalla PK, Wong LY, Winnik B, Buckley B. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010;221(2):329–334. doi:10.1016/j.expneurol.2009.11.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2009.11.018</ArticleId>
            <ArticleId IdType="pmc">PMC2812670</ArticleId>
            <ArticleId IdType="pubmed">19948168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamura S, Ohoyama K, Nagase H, Okada M. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology. 2009;57(3):322–331. doi:10.1016/j.neuropharm.2009.05.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2009.05.005</ArticleId>
            <ArticleId IdType="pubmed">19482038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asanuma M, Miyazaki I, Diaz-Corrales FJ, et al. Neuroprotective effects of zonisamide target astrocyte. Ann Neurol. 2010;67(2):239–249. doi:10.1002/ana.21885</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21885</ArticleId>
            <ArticleId IdType="pubmed">20225289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa C, Tozzi A, Luchetti E, et al. Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol. 2010;221(1):217–224. doi:10.1016/j.expneurol.2009.11.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2009.11.002</ArticleId>
            <ArticleId IdType="pubmed">19913015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sano H, Murata M, Nambu A. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson’s disease. J Neurochem. 2015;134(2):371–381. doi:10.1111/jnc.13116</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13116</ArticleId>
            <ArticleId IdType="pubmed">25857446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci Res. 2001;41(4):397–399. doi:10.1016/S0168-0102(01)00298-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0168-0102(01)00298-X</ArticleId>
            <ArticleId IdType="pubmed">11755227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsunaga S, Kishi T, Iwata N. Combination therapy with zonisamide and antiparkinson drugs for Parkinson’s disease: a meta-analysis. J Alzheimers Dis. 2017;56(4):1229–1239. doi:10.3233/JAD-161068</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-161068</ArticleId>
            <ArticleId IdType="pubmed">28157097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dainippon Sumitomo Pharma Co. Parkinson’s disease drug “TRERIEF” obtained manufacturing and marketing approval [Internet]; 2009. Available from: https://www.ds-pharma.com/ir/news/2009/20090121.html. Accessed April20, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disorders. 2018;33(8):1248–1266. doi:10.1002/mds.27372</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.27372</ArticleId>
            <ArticleId IdType="pubmed">29570866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odawara T, Shiozaki K, Togo T, Hirayasu Y. Administration of zonisamide in three cases of dementia with Lewy bodies. Psychiatry Clin Neurosci. 2010;64(3):327–329. doi:10.1111/j.1440-1819.2010.02075.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1819.2010.02075.x</ArticleId>
            <ArticleId IdType="pubmed">20408991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata M, Odawara T, Hasegawa K, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a Randomized Double-Blind Phase 2 Study. Neurology. 2018;90(8):e664–e672. doi:10.1212/WNL.0000000000005010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000005010</ArticleId>
            <ArticleId IdType="pmc">PMC5818167</ArticleId>
            <ArticleId IdType="pubmed">29367449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738–750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12815652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1202204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308. doi:10.1212/WNL.44.12.2308</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.44.12.2308</ArticleId>
            <ArticleId IdType="pubmed">7991117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arai Y, Kudo K, Hosokawa T, Washio M, Miura H, Hisamichi S. Reliability and validity of the Japanese version of the Zarit Caregiver burden interview. Psychiatry Clin Neurosci. 1997;51(5):281–287. doi:10.1111/j.1440-1819.1997.tb03199.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1819.1997.tb03199.x</ArticleId>
            <ArticleId IdType="pubmed">9413874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toya S, Murata M, Odawara T, et al. Long-term efficacy for parkinsonism and safety of zonisamide in patients with dementia with Lewy bodies: a phase III trial. Neurology. 2019;92(15Supplement): P4.1–011.</Citation>
        </Reference>
        <Reference>
          <Citation>Hasegawa K, Kenji K, Maruyama H, Konishi O, Toya S, Odawara T. Efficacy and safety of zonisamide in dementia with Lewy bodies patients with Parkinsonism: a post hoc analysis of two randomized, double-blind, placebo-controlled trials. J Alzheimers Dis. 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7902955</ArticleId>
            <ArticleId IdType="pubmed">33337365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sumitomo Dainippon Pharma Co. Sumitomo dainippon pharma obtains approval in Japan for TRERIEF, a therapeutic agent for Parkinson’s disease, for an additional indication of Parkinsonism in dementia with Lewy bodies [Internet]; 2018. Available from: https://www.ds-pharma.com/ir/news/2018/20180702.html. Accessed April20, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaur U, Chauhan I, Gambhir IS, Chakrabarti SS. Antiepileptic drug therapy in the elderly: a clinical pharmacological review. Acta Neurol Belg. 2019;119(2):163–173. doi:10.1007/s13760-019-01132-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13760-019-01132-4</ArticleId>
            <ArticleId IdType="pubmed">30953298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves wearing-off in Parkinson’s disease: a Randomized, Double-Blind Study. Mov Disord. 2015;30(10):1343–1350. doi:10.1002/mds.26286</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26286</ArticleId>
            <ArticleId IdType="pubmed">26094993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata M, Hasegawa K, Kanazawa I, Shirakura K, Kochi K, Shimazu R. Randomized placebo-controlled trial of zonisamide in patients with Parkinson’s disease. Neurol Clin Neurosci. 2016;4(1):10–15. doi:10.1111/ncn3.12026</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ncn3.12026</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
